LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
St. James's Hospital
Dublín, IrlandaPublicaciones en colaboración con investigadores/as de St. James's Hospital (4)
2012
-
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study
The Lancet Oncology, Vol. 13, Núm. 1, pp. 33-42
-
Treatment rationale study design for the MetLung trial: A randomized, double-blind phase III study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV met-positive non-small-cell lung cancer
Clinical Lung Cancer, Vol. 13, Núm. 6, pp. 500-504
2011
-
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study
The Lancet Oncology, Vol. 12, Núm. 1, pp. 30-37
-
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
The Lancet Oncology, Vol. 12, Núm. 8, pp. 795-805